BD (Becton, Dickinson and Company) announced new data on September 26, 2024, highlighting the effectiveness of its advanced artificial intelligence technology in identifying controlled substance diversion within operating rooms. A research study conducted at an Ochsner Health medical center and published in the American Journal of Health-System Pharmacy (AJHP) demonstrated the software's capabilities.
The study revealed a 55% increase in charting discrepancies detected after implementing BD HealthSight™ Diversion Management software, compared to previous manual processes. This increase is attributed to the software's ability to track a broader range of discrepancies, including whole dose waste and cancelled transactions.
Furthermore, the software improved efficiency in reconciling potential drug diversion incidents, with the percentage of resolved incidents increasing by 14%. The time required for an auditor to review referred cases of potential diversion was reduced from an average of three business days to 50 minutes, enhancing operational effectiveness for health systems.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.